Do you want to read an article? Please log in or register.
A pooled analysis of datopotamab deruxtecan in patients with EGFR-mutated NSCLC
Lung, Respiratory and Thoracic Cancer
Related content
WCLC 2024
Lung, Respiratory and Thoracic Cancer
TROPION-Lung01: Datopotamab deruxtecan shows a clinically meaningful trend toward improved OS versus docetaxel in patients with NSCLC
ESMO 2024
Lung, Respiratory and Thoracic Cancer
MARIPOSA-2: OS data continued to favor amivantamab plus chemotherapy over chemotherapy alone in patients with EGFR-mutated NSCLC
Lung, Respiratory and Thoracic Cancer
LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154)
Lung Cancer (Auckl)
Luo FX, Arter Z, Ou SI, Nagasaka M
doi: 10.2147/LCTT.S520833
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Befotertinib for patients with pretreated EGFR T790M mutated locally advanced or metastatic NSCLC: Final overall survival results from a phase 2 trial
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Lu S, Zhang Y, Zhang G, Zhou J, Cang S, Cheng Y, Wu G, Cao P, Lv D, Jian H, Jin X, Chen C, Tian P, Wang K, Jiang G, Chen G, Chen Q, Zhao H, Ding C, Guo R, Sun G, Wang B, Jiang L, Liu Z, Fang J, Yang J, Zhuang W, Liu Y, Zhang J, Pan Y, Chen J, Yu Q, Zhao M, Cui J, Li D, Yi T, Yu Z, Yang Y, Zhang Y, Zhi X, Huang Y, Wu R, Chen L, Zang A, Cao L, Li Q, Li X, Song Y, Wang D, Zhang S, Ding L, Zhang L, Ji D, Shen Z
doi: 10.1016/j.lungcan.2024.107901
COMMENTED
Breast Cancer
A Pooled Analysis of Trastuzumab Deruxtecan in Patients With HER2-Positive Metastatic Breast Cancer With Brain Metastases
★ 3
Recommended and commented by
Prof. Dr Beat Thürlimann, Faculty Member
Ann Oncol
André F, Cortés J, Curigliano G, Modi S, Li W, Park YH, Chung WP, Kim SB, Yamashita T, Pedrini JL, Im SA, Tseng LM, Harbeck N, Krop I, Nakatani S, Tecson K, Ashfaque S, Egorov A, Hurvitz SA
doi: 10.1016/j.annonc.2024.08.2347
ESMO 2024
Lung, Respiratory and Thoracic Cancer
MARIPOSA: Amivantamab plus lazertinib reduced the incidence of acquired MET and EGFR resistance alterations versus osimertinib in patients with NSCLC
ELCC 2025
Lung, Respiratory and Thoracic Cancer
LAURA: Improved trend for OS benefit with osimertinib versus placebo in patients with unresectable stage III EGFR-mutant NSCLC
Lung, Respiratory and Thoracic Cancer
Exploration of clinical Biomarkers for guiding treatment selection between chemotherapy and combination therapy with Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Mutant NSCLC patients after EGFR-TKI Therapy: The SPIRAL-STEP study
Lung Cancer
Morimoto K, Yamada T, Furuya N, Tanaka H, Yoshimura A, Oba T, Hibino M, Fukuda T, Goto Y, Nakao A, Ogusu S, Okazaki Y, Harada T, Ota T, Masubuchi K, Mikami K, Hata T, Matsumoto S, Honda R, Date K, Chihara Y, Takayama K
doi: 10.1016/j.lungcan.2025.108447
Lung, Respiratory and Thoracic Cancer
Improved event-free survival after complete or major pathologic response in patients with resectable NSCLC treated with neoadjuvant chemoimmunotherapy regardless of adjuvant treatment: a systematic review and individual patient data meta-analysis
J Thorac Oncol
Marinelli D, Nuccio A, Di Federico A, Ambrosi F, Bertoglio P, Faccioli E, Ferrara R, Ferro A, Giusti R, Guerrera F, Mammana M, Pittaro A, Sepulcri M, Viscardi G, Gallina FT
doi: 10.1016/j.jtho.2024.09.1443